NASDAQ Healthcare Biotechnology MNKD

MannKind Corporation

$ 3.94 0.51 %

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

CEO: Michael E. Castagna - https://www.mannkindcorp.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$8.5 115.74 %

Recommandation

Buy

DCF

$ -38.87

Loading data...

MNKD vs S&P500

Loading data...

No data available.

Quick ratio

1.50

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-56.29

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.07

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

45.59 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

1.80 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

8.00

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-7.38

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.04

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
-4.41 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.39 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.59 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.